Donna Joyce Webb

US Patent:

54878900, Jan 30, 1996

Filed:

Jan 24, 1994

Appl. No.:

8/186136

Inventors:

Ronald P. Taylor - Charlottesville VA
William M. Sutherland - Earlysville VA
Craig Reist - Charlottesville VA
Eleanor L. Wright - Earlysville VA
Donna Webb - Charlottesville VA
Ronald Labuguen - Charlottesville VA

Assignee:

University of Virginia Patent Foundation - Charlottesville VA

International Classification:

A61K 39395
A61K 3940
A61K 3942

US Classification:

4241361

Abstract:

Mammalian red blood cells are used to safely and rapidly neutralize and/or clear antigens or immunogens from the circulatory system by binding to the RBC a monoclonal antibody specific for a receptor (CR1) on the RBC, which monoclonal antibody is chemically bound to a second Mab specific for the antigen to be cleared from the circulatory system. These chemically cross-linked monoclonal antibody heteropolymers may be injected directly into the patient's circulatory system. Alternatively, red blood cells, extracted from the patient or provided by a suitable donor, are bound to the Mab complex and returned to the system.

US Patent:

54705703, Nov 28, 1995

Filed:

Dec 6, 1993

Appl. No.:

8/161812

Inventors:

Ronald P. Taylor - Charlottesville VA
William M. Sutherland - Earlysville VA
Craig Reist - Charlottesville VA
Eleanor L. Wright - Earlysville VA
Donna Webb - Charlottesville VA
Ronald Labuguen - Charlottesville VA

Assignee:

University of Virginia Patent Foundation - Charlottesville VA

International Classification:

A61K 3518
A61K 39395
A61K 3940
A61K 3942

US Classification:

424 9373

Abstract:

Mammalian red blood cells are used to safely and rapidly neutralize and/or clear antigens or immunogens from the circulatory system by binding to the RBC a monoclonal antibody specific for a receptor (CR1) on the RBC, which monoclonal antibody is chemically bound to a second Mab specific for the antigen to be cleared from the circulatory system. These chemically cross-linked monoclonal antibody heteropolymers may be injected directly into the patient's circulatory system. Alternatively, red blood cells, extracted from the patient or provided by a suitable donor, are bound to the Mab complex and returned to the system.

US Patent:

59027878, May 11, 1999

Filed:

Jun 30, 1997

Appl. No.:

8/885764

Inventors:

Steven L. Gonias - Charlottesville VA
Donna J. Webb - Charlottesville VA

Assignee:

The University of Virginia Patent Foundation - Charlottesville VA

International Classification:

C07K14/00

US Classification:

514 2

Abstract:

Chemically modified. alpha. -macroglobulin is conformationally locked by cross-linking. alpha. sub. 2 M with a bi-functional peptide crosslinker, and then modified with methylamine, to provide conformational intermediates with limited conformational change. These modified compounds have a high binding affinity for inflammatory cytokines including TNF-. alpha. and IL-1. beta. When administered in vivo, the modified. alpha. sub. 2 M (MAC) protects against development of septic shock, and is an effective treatment aid in treating mammals with established septic shock.

US Patent:

63295008, Dec 11, 2001

Filed:

May 13, 1999

Appl. No.:

9/311352

Inventors:

Donna J. Webb - Charlottesville VA
Steven L. Gonias - Charlottesville VA

Assignee:

University of Virginia Patent Foundation - Charlottesville VA

International Classification:

C07K 706
C07K 14435
A61K 3808
A61K 3817

US Classification:

530328

Abstract:

The present invention relates to a composition and method for inhibiting TGF-. beta. activity. The composition comprises a TGF-. beta. neutralizing peptide derived from. alpha. sub. 2 -macroglobulin that binds to TGF-. beta. and inhibits TGF-. beta. activity.